Jürgen E. Gschwend

16.7k total citations · 3 hit papers
314 papers, 10.1k citations indexed

About

Jürgen E. Gschwend is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Oncology. According to data from OpenAlex, Jürgen E. Gschwend has authored 314 papers receiving a total of 10.1k indexed citations (citations by other indexed papers that have themselves been cited), including 162 papers in Pulmonary and Respiratory Medicine, 102 papers in Surgery and 72 papers in Oncology. Recurrent topics in Jürgen E. Gschwend's work include Prostate Cancer Treatment and Research (112 papers), Prostate Cancer Diagnosis and Treatment (80 papers) and Bladder and Urothelial Cancer Treatments (79 papers). Jürgen E. Gschwend is often cited by papers focused on Prostate Cancer Treatment and Research (112 papers), Prostate Cancer Diagnosis and Treatment (80 papers) and Bladder and Urothelial Cancer Treatments (79 papers). Jürgen E. Gschwend collaborates with scholars based in Germany, United States and Netherlands. Jürgen E. Gschwend's co-authors include Tobias Maurer, Matthias Eiber, Markus Schwaiger, Matthias Heck, Hubert Kübler, Bernhard Haller, Isabel Rauscher, Hans‐Jürgen Wester, Michael Souvatzoglou and Margitta Retz and has published in prestigious journals such as Journal of Biological Chemistry, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Jürgen E. Gschwend

302 papers receiving 9.9k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Evaluation of Hybrid ⁶⁸Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy

2015 813 citations Matthias Eiber, Tobias Maurer et al. profile →
Diagnostic Efficacy of ⁶⁸ Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer

2015 595 citations Tobias Maurer, Jürgen E. Gschwend et al. profile →
Current use of PSMA–PET in prostate cancer management

2016 461 citations Tobias Maurer, Matthias Eiber et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jürgen E. Gschwend Germany	49	5.9k	3.3k	2.4k	2.1k	1.9k	314	10.1k
Michael A. Gorin United States	49	5.9k 1.0×	2.6k 0.8×	2.3k 0.9×	1.8k 0.8×	2.3k 1.3×	327	9.3k
Manfred P. Wirth Germany	48	4.9k 0.8×	800 0.2×	2.3k 1.0×	1.6k 0.8×	2.2k 1.2×	442	9.3k
Chris H. Bangma Netherlands	56	7.1k 1.2×	774 0.2×	2.4k 1.0×	2.1k 1.0×	1.6k 0.9×	213	9.9k
Wolfgang Horninger Austria	47	4.8k 0.8×	1.4k 0.4×	1.3k 0.5×	901 0.4×	1.2k 0.7×	256	7.1k
Bin S. Teh United States	48	4.0k 0.7×	1.6k 0.5×	2.0k 0.8×	2.0k 0.9×	1.2k 0.7×	374	8.4k
Axel S. Merseburger Germany	50	9.6k 1.6×	1.9k 0.6×	4.1k 1.7×	2.5k 1.2×	5.9k 3.2×	421	14.3k
Louis Lacombe Canada	39	3.0k 0.5×	1.1k 0.3×	2.7k 1.1×	3.4k 1.6×	1.6k 0.9×	179	7.2k
Sam S. Chang United States	45	3.1k 0.5×	912 0.3×	4.9k 2.0×	2.4k 1.1×	2.2k 1.2×	209	9.9k
Matthew I. Milowsky United States	51	3.5k 0.6×	1.3k 0.4×	5.4k 2.3×	3.2k 1.5×	2.7k 1.5×	274	10.2k
Kevin M. Slawin United States	55	6.9k 1.2×	596 0.2×	1.5k 0.6×	1.9k 0.9×	2.0k 1.1×	183	10.0k

Countries citing papers authored by Jürgen E. Gschwend

Since Specialization

Citations

This map shows the geographic impact of Jürgen E. Gschwend's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jürgen E. Gschwend with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jürgen E. Gschwend more than expected).

Fields of papers citing papers by Jürgen E. Gschwend

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jürgen E. Gschwend. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jürgen E. Gschwend. The network helps show where Jürgen E. Gschwend may publish in the future.

Co-authorship network of co-authors of Jürgen E. Gschwend

This figure shows the co-authorship network connecting the top 25 collaborators of Jürgen E. Gschwend. A scholar is included among the top collaborators of Jürgen E. Gschwend based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jürgen E. Gschwend. Jürgen E. Gschwend is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kirchhoff, Florian, et al.. (2025). Self-efficacy in long-term prostate cancer survivors. International Journal of Clinical and Health Psychology. 25(4). 100634–100634.

Dinkel, Andreas, et al.. (2024). Gesundheitsprobleme nach radikaler Prostatektomie. PubMed. 64(1). 29–37. 2 indexed citations

Pan, Qi, Thomas Engleitner, Rupert Öllinger, et al.. (2024). CDK4/6 inhibition initiates cell cycle arrest by nuclear translocation of RB and induces a multistep molecular response. Cell Death Discovery. 10(1). 453–453. 6 indexed citations

Powles, Thomas, Zoe J. Assaf, Viraj Degaonkar, et al.. (2023). Updated Overall Survival by Circulating Tumor DNA Status from the Phase 3 IMvigor010 Trial: Adjuvant Atezolizumab Versus Observation in Muscle-invasive Urothelial Carcinoma. European Urology. 85(2). 114–122. 61 indexed citations

Herkommer, Kathleen, Valentin H. Meissner, Andreas Dinkel, et al.. (2023). Prevalence, lifestyle, and risk factors of erectile dysfunction, premature ejaculation, and low libido in middle‐aged men: first results of the Bavarian Men's Health‐Study. Andrology. 12(4). 801–808. 9 indexed citations

Zhao, Yuling, Qi Pan, Zhichao Tong, et al.. (2021). Combination of Talazoparib and Palbociclib as a Potent Treatment Strategy in Bladder Cancer. Journal of Personalized Medicine. 11(5). 340–340. 12 indexed citations

Bajorin, Dean F., J. Alfred Witjes, Jürgen E. Gschwend, et al.. (2021). First results from the phase 3 CheckMate 274 trial of adjuvant nivolumab vs placebo in patients who underwent radical surgery for high-risk muscle-invasive urothelial carcinoma (MIUC).. Journal of Clinical Oncology. 39(6_suppl). 391–391. 30 indexed citations

Schmid, Sebastian C., Florestan Koll, Claus Rödel, et al.. (2020). Radiation therapy before radical cystectomy combined with immunotherapy in locally advanced bladder cancer – study protocol of a prospective, single arm, multicenter phase II trial (RACE IT). BMC Cancer. 20(1). 8–8. 19 indexed citations

Schmid, Sebastian C., Anna Katharina Seitz, Bernhard Haller, et al.. (2020). Final results of the PräVAC trial: prevention of wound complications following inguinal lymph node dissection in patients with penile cancer using epidermal vacuum-assisted wound closure. World Journal of Urology. 39(2). 613–620. 8 indexed citations

10.

Heck, Matthias, Margitta Retz, Gregor Weirich, et al.. (2018). Molecular Lymph Node Status for Prognostic Stratification of Prostate Cancer Patients Undergoing Radical Prostatectomy with Extended Pelvic Lymph Node Dissection. Clinical Cancer Research. 24(10). 2342–2349. 10 indexed citations

11.

Koll, Florestan, Klaus Mantwill, Klaus‐Peter Janssen, et al.. (2018). The Oncolytic Adenovirus XVir-N-31 as a Novel Therapy in Muscle-Invasive Bladder Cancer. Human Gene Therapy. 30(1). 44–56. 18 indexed citations

12.

Thalgott, Mark, et al.. (2015). Diagnostic imaging of urolithiais. Current recommendations and new developments. Urologe A. 54(7). 948–955. 1 indexed citations

13.

Escudier, Bernard, Viktor Grünwald, Alain Ravaud, et al.. (2014). Phase II Results of Dovitinib (TKI258) in Patients with Metastatic Renal Cell Cancer. Clinical Cancer Research. 20(11). 3012–3022. 49 indexed citations

14.

Hatzichristodoulou, Georgios, Christoph Meisner, Jürgen E. Gschwend, Arnulf Stenzl, & Sven Lahme. (2013). Extracorporeal Shock Wave Therapy in Peyronie's Disease: Results of a Placebo-Controlled, Prospective, Randomized, Single-Blind Study. The Journal of Sexual Medicine. 10(11). 2815–2821. 72 indexed citations

15.

Angevin, Eric, José A. López-Martín, Chia‐Chi Lin, et al.. (2013). Phase I Study of Dovitinib (TKI258), an Oral FGFR, VEGFR, and PDGFR Inhibitor, in Advanced or Metastatic Renal Cell Carcinoma. Clinical Cancer Research. 19(5). 1257–1268. 103 indexed citations

16.

Hatzichristodoulou, Georgios, et al.. (2013). Surgical Management of Penile Fracture and Long-Term Outcome on Erectile Function and Voiding. The Journal of Sexual Medicine. 10(5). 1424–1430. 48 indexed citations

17.

Maurer, Tobias, Thomas Horn, Ambros J. Beer, Matthias Eiber, & Jürgen E. Gschwend. (2013). Funktionelle Bildgebung beim Harnblasenkarzinom. Der Urologe. 52(4). 509–514. 1 indexed citations

18.

Vogler, Meike, Henning Walczak, Dominic Stadel, et al.. (2009). Small Molecule XIAP Inhibitors Enhance TRAIL-Induced Apoptosis and Antitumor Activity in Preclinical Models of Pancreatic Carcinoma. Cancer Research. 69(6). 2425–2434. 121 indexed citations

19.

Vogler, Meike, Henning Walczak, Dominic Stadel, et al.. (2008). Targeting XIAP Bypasses Bcl-2–Mediated Resistance to TRAIL and Cooperates with TRAIL to Suppress Pancreatic Cancer Growth In vitro and In vivo. Cancer Research. 68(19). 7956–7965. 135 indexed citations

20.

Gschwend, Jürgen E., William R. Fair, & C. Thomas Powell. (2000). Bryostatin 1 Induces Prolonged Activation of Extracellular Regulated Protein Kinases in and Apoptosis of LNCaP Human Prostate Cancer Cells Overexpressing Protein Kinase Cα. Molecular Pharmacology. 57(6). 1224–1234. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact